Free Trial

Bausch Health Companies (BHC) Competitors

Bausch Health Companies logo
$7.44 -0.22 (-2.81%)
As of 01/17/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BHC vs. QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, and ELAN

Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

Bausch Health Companies vs.

Bausch Health Companies (NYSE:BHC) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Bausch Health Companies received 110 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 61.47% of users gave Bausch Health Companies an outperform vote while only 60.73% of users gave Qiagen an outperform vote.

CompanyUnderperformOutperform
Bausch Health CompaniesOutperform Votes
359
61.47%
Underperform Votes
225
38.53%
QiagenOutperform Votes
249
60.73%
Underperform Votes
161
39.27%

78.7% of Bausch Health Companies shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Qiagen has a net margin of 4.73% compared to Bausch Health Companies' net margin of -1.88%. Qiagen's return on equity of 13.43% beat Bausch Health Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Companies-1.88% -755.86% 5.11%
Qiagen 4.73%13.43%8.10%

Bausch Health Companies presently has a consensus target price of $7.75, suggesting a potential upside of 4.24%. Qiagen has a consensus target price of $51.50, suggesting a potential upside of 11.96%. Given Qiagen's stronger consensus rating and higher probable upside, analysts plainly believe Qiagen is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Companies
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Qiagen
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.56

Qiagen has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.76B0.31-$592M-$0.48-15.49
Qiagen$1.97B5.34$341.30M$0.39117.94

Bausch Health Companies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

In the previous week, Qiagen had 3 more articles in the media than Bausch Health Companies. MarketBeat recorded 13 mentions for Qiagen and 10 mentions for Bausch Health Companies. Qiagen's average media sentiment score of 0.73 beat Bausch Health Companies' score of 0.67 indicating that Qiagen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch Health Companies
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Qiagen
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Qiagen beats Bausch Health Companies on 13 of the 18 factors compared between the two stocks.

Get Bausch Health Companies News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHC vs. The Competition

MetricBausch Health CompaniesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$2.69B$6.58B$5.36B$19.88B
Dividend YieldN/A2.94%5.13%3.70%
P/E Ratio-15.499.8389.4741.44
Price / Sales0.31305.871,263.7017.21
Price / Cash1.0961.4443.7519.84
Price / Book-32.336.055.325.73
Net Income-$592M$154.62M$122.60M$993.95M
7 Day Performance-5.65%-1.68%0.69%3.14%
1 Month Performance-3.19%-2.35%1.55%1.89%
1 Year Performance-8.88%1.02%27.25%19.67%

Bausch Health Companies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHC
Bausch Health Companies
3.3235 of 5 stars
$7.44
-2.8%
$7.75
+4.2%
-8.9%$2.69B$8.76B-15.4920,270Short Interest ↓
News Coverage
Positive News
High Trading Volume
QGEN
Qiagen
4.0945 of 5 stars
$46.02
+3.0%
$51.50
+11.9%
-0.2%$10.50B$1.97B118.005,967Short Interest ↓
News Coverage
PCVX
Vaxcyte
1.9841 of 5 stars
$80.35
-0.9%
$145.71
+81.3%
+35.7%$10.01BN/A-17.47160Insider Trade
Analyst Revision
News Coverage
ASND
Ascendis Pharma A/S
3.6129 of 5 stars
$131.47
+1.8%
$192.07
+46.1%
-3.2%$7.98B$327.43M-16.27640Short Interest ↓
ROIV
Roivant Sciences
3.6806 of 5 stars
$10.67
+0.4%
$17.93
+68.0%
+3.6%$7.77B$129.13M1.89860Insider Trade
Options Volume
Positive News
RVMD
Revolution Medicines
4.4701 of 5 stars
$42.24
+1.1%
$66.25
+56.8%
+50.2%$7.11B$742,000.00-11.77250News Coverage
LNTH
Lantheus
4.5418 of 5 stars
$94.50
-1.4%
$131.86
+39.5%
+65.5%$6.57B$1.50B15.72700Analyst Forecast
Short Interest ↑
BPMC
Blueprint Medicines
1.6641 of 5 stars
$100.87
+15.4%
$122.72
+21.7%
+38.6%$6.41B$434.42M-47.81640Analyst Forecast
Insider Trade
Short Interest ↑
Analyst Revision
BBIO
BridgeBio Pharma
4.0863 of 5 stars
$32.78
+12.7%
$48.08
+46.7%
-8.5%$6.20B$217.77M-13.60400Short Interest ↑
High Trading Volume
LEGN
Legend Biotech
2.5041 of 5 stars
$31.86
-5.2%
$80.62
+153.0%
-45.5%$5.82B$520.18M-33.541,800Short Interest ↓
News Coverage
ELAN
Elanco Animal Health
4.415 of 5 stars
$11.57
+1.2%
$16.43
+42.0%
-18.8%$5.72B$4.45B28.939,800

Related Companies and Tools


This page (NYSE:BHC) was last updated on 1/18/2025 by MarketBeat.com Staff
From Our Partners